(Press-News.org) SEATTLE – Pancreas cancer tumors spread quickly and are notoriously resistant to treatment, making them among the deadliest of malignancies. Their resistance to chemotherapy stems in part from a unique biological barrier the tumor builds around itself. Now scientists at Fred Hutchinson Cancer Research Center have found a way to break through that defense, and their research represents a potential breakthrough in the treatment of pancreas cancer.
In a paper to be published in the March 20 issue of Cancer Cell, senior author Sunil Hingorani, M.D., Ph.D., an associate member of the Hutchinson Center's Clinical Research and Public Health Sciences divisions, and colleagues describe the biological mechanisms of how the tumor barrier is formed and detail a newly discovered way to break it down. Their research significantly increased the length of survival in a genetically engineered mouse model of the disease. Early clinical trials in humans are under way at a few sites in the U.S. and Europe, including Seattle Cancer Care Alliance, the Hutchinson Center's patient treatment arm. Details about the open clinical trial can be found here: http://clinicaltrials.gov/show/NCT01453153
Using a mouse model developed by Hingorani, the scientists combined gemcitabine, the current standard chemotherapy used to treat pancreatic ductal adenocarcinomas, with an enzyme called PEGPH20. When they infused the combination into specially engineered mice whose pancreas tumors mimic those of human pancreas cancer, the combination broke down the matrix barrier within the tumors and allowed the chemotherapy to permeate freely and spread throughout the cancerous tissue. The result was a 70 percent increase in survival time of the mice after the start of treatment, from 55 to 92 days.
"This represents the largest survival increase we've seen in any of the studies done in a preclinical model, and it rivals the very best results reported in humans," Hingorani said.
Unlike most solid tumors, pancreas tumors use a two-pronged defense to keep small molecules, such as those contained in chemotherapy, from entering: a vastly reduced blood supply and the creation of a strong fibroinflammatory response. The latter includes the production of fibroblasts, immune cells and endothelial cells that become embedded within a dense and complex extracellular matrix throughout the tumor. One major component of this matrix is a substance called hyaluronan, or hyaluronic acid (HA). HA is a glycosaminoglycan, a complex sugar that occurs naturally in the body and is secreted at extremely high levels by pancreas cancer cells.
Hingorani and colleagues discovered that the fibroinflammatory response creates unusually high interstitial fluid pressures that collapse the tumor's blood vessels. This in turn prevents chemotherapy agents from entering the tumors. The researchers found that HA is the main biological cause of the elevated pressures that leads to blood vessel collapse.
"That's the primary reason pancreas cancers are resistant to everything we've thrown at them: because none of the drugs get into the tumor. It's physics first, before we even get to the intrinsic biology," Hingorani said.
Administering the enzyme/gemcitabine combination degrades HA in the tumor barrier and results in rapid reduction of the interstitial fluid pressure. This in turn opens the blood vessels and permits high concentrations of chemotherapy to reach the tumor.
"Being able to deliver the drugs effectively into the tumor resulted in improved survival as well as the realization that pancreas cancer may be more sensitive to conventional chemotherapy than we previously thought," Hingorani said.
Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer-related death in the United States. Overall five-year survival is less than 5 percent with a median survival of four to six months.
###
Grants from the National Cancer Institute, the Giles W. and Elise G. Mead Foundation, Safeway and several individuals supported the research. Collaborators from the University of Washington and the Translational Genomics Research Institute in Scottsdale, Ariz., contributed to the study.
At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Our researchers, including three Nobel laureates, bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, please visit fhcrc.org.
CONTACT
Dean Forbes
206-667-2896
dforbes@fhcrc.org
END
Putting the brakes on an abundant growth-promoting protein causes breast tumors to regress, according to a study published on March 19th in the Journal of Experimental Medicine.
Triple-negative breast tumors lack all of the known growth receptors that serve as treatment targets in other types of breast cancer, making this the most clinically challenging subtype of the disease. Patients with these tumors tend to relapse earlier and have shorter disease-free survival.
Andrei Goga and colleagues now show that triple-negative breast tumors express elevated levels of the ...
People whose blood pressure drops rapidly when they move from lying down to standing, known as orthostatic hypotension, may have a higher risk of developing heart failure, according to research published in Hypertension, an American Heart Association journal.
The link between orthostatic hypotension and heart failure was stronger in people 45-55 years old compared to those 56-64, researchers said. High blood pressure, which was present in over half of people who developed heart failure, may be partially responsible for the association.
Over an average 17.5 years of follow-up, ...
EDITOR'S PICK
A clearer understanding of glaucoma | Back to top
Glaucoma is one of the leading causes of vision loss and blindness worldwide. In glaucoma patients, the optic nerve, which relays information from the eye to the brain, is damaged, though the molecular cause of nerve damage is unclear. Dr. Simon John, from Tufts University in Boston, and colleagues specifically wanted to understand the earliest events that lead to optic nerve damage in glaucoma. Using a mouse model of the disease, the researchers showed that inflammatory immune cells called monocytes cross ...
Physical violence, sexual abuse and other forms of childhood and adult trauma are major factors fueling the epidemic of HIV/AIDS among American women. Scientists have known for years that traumatized women are at greater risk of becoming infected.
Now, two new studies from the University of California, San Francisco (UCSF) and Harvard Medical School demonstrate that a high rate of trauma among women already infected with HIV also plays a role in the epidemic.
Described in back-to-back papers in the journal AIDS and Behavior, the new work demonstrates that women with ...
Glaucoma is one of the leading causes of vision loss and blindness worldwide. In glaucoma patients, the optic nerve, which relays information from the eye to the brain, is damaged, though the molecular cause of nerve damage is unclear. Dr. Simon John, from Tufts University in Boston, and colleagues specifically wanted to understand the earliest events that lead to optic nerve damage in glaucoma. Using a mouse model of the disease, the researchers showed that inflammatory immune cells called monocytes cross blood vessels and invade the optic nerve. Remarkably, mice treated ...
CHICAGO – The minimally invasive hernia repair procedure known as total extraperitoneal inguinal hernioplasty (TEP) was associated with higher patient satisfaction, less chronic pain and less impairment of inguinal (groin) sensation compared to the open surgical Lichtenstein repair, according to a study published in the March issue of Archives of Surgery, one of the JAMA/Archives journals.
Chronic pain and hypoesthesia (reduced sensitivity) are increasingly measured after inguinal hernia repair but few randomized clinical trials have compared TEP with Lichtenstein repair, ...
CHICAGO – An antioxidant combination of vitamin E, vitamin C and α-lipoic acid (E/C/ALA) was not associated with changes in some cerebrospinal fluid biomarkers related to Alzheimer disease in a randomized controlled trial, according to a study published Online First by Archives of Neurology, one of the JAMA/Archives journals.
Oxidative damage in the brain is associated with aging and is widespread in Alzheimer disease (AD) patients. Some observational studies have suggested that an antioxidant-rich diet may reduce the risk of AD, but antioxidant randomized clinical ...
CHICAGO – Patients with obstructive sleep apnea who undergo surgery for their condition should be closely monitored after their procedures are performed but may not need to be in an intensive care unit, according to a report published Online First by Archives of Otolaryngology – Head & Neck Surgery, one of the JAMA/Archives journals.
Surgical procedures in patients with sleep apnea (a sleep disorder characterized by pauses in breathing) have traditionally been considered dangerous and potentially life threatening if not monitored with caution because these patients are ...
A Harvard archaeologist has dramatically simplified the process of finding early human settlements by using computers to scour satellite images for the tell-tale clues of human habitation, and in the process uncovered thousands of new sites that might reveal clues to the earliest complex human societies.
As described in a paper published March 19 in the Proceedings of the National Academy of Sciences, Jason Ur, the John L. Loeb Associate Professor of the Social Sciences, worked with Bjoern Menze, a research affiliate in MIT's Computer Science and Artificial Intelligence ...
LA JOLLA, Calif., March 19, 2012 – Drug resistance is a serious problem for cancer patients—over time, a therapy that was once providing some benefit simply stops working. Scientists at Sanford-Burnham Medical Research Institute (Sanford-Burnham) recently discovered how cancer cells develop resistance to a drug called MLN4924. This experimental therapy is currently being tested in a number of Phase I and Phase I/II clinical trials to determine its efficacy against several different types of cancer, including multiple myeloma, leukemia, and lymphoma.
Published online March ...
